GPCR
Structure Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$35.00
−0.28%Sep 8, 2026, 12:00 UTC
Structure Therapeutics reported positive clinical data for its oral small molecule amylin receptor agonist ACCG-2671 and GLP-1 receptor agonist aleniglipron for chronic weight management, including Phase 1/2a results for ACCG-2671 and Phase 2 OLE results for aleniglipron showing up to 16.2% mean body weight reduction at 72 weeks.
Source:Aug 21, 2026, 18:21 UTC
Structure Therapeutics is advancing its oral GLP-1 candidate aleniglipron into Phase 3 studies, with pivotal data expected in Q4 2028.
Source:Aug 6, 2026, 00:00 UTC
Structure Therapeutics Inc. reported a net loss of $106.2 million for Q2 2026, with research and development expenses of $100.1 million and general and administrative expenses of $18.6 million.
Jun 8, 2026, 03:44 UTC
Structure Therapeutics is advancing its oral amylin receptor agonist pipeline, with lead candidate ACCG-2671 expected to enter multiple ascending dose studies in Q3 and a second candidate ACCG-3535 beginning clinical trials in Q4.
Source:Jun 8, 2026, 03:44 UTC
Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight loss, and is on track to initiate a Phase 3 registrational trial in Q3 2026.
Source: